Curaleaf Executive Chairman Boris Jordan [on International Business] Says Consumer Habits Are Slower, German Market Is Closer To "California Medical"; Growing Quickly And Exponentially; Uk Very Pharmaceutical Medical, Run Almost Like Pharma Company; Poland Looking A Lot Like Germany; Working On Turkey For Last Two-years; Turks Grow A Lot Of Hemp So They Know Industry, Mostly Industrial
Portfolio Pulse from Benzinga Newsdesk
Curaleaf's Executive Chairman, Boris Jordan, discusses the company's international strategy, highlighting slower consumer habits and market similarities between Germany and California. The UK market is described as pharmaceutical, while Poland resembles Germany. Curaleaf has been working in Turkey, leveraging its hemp industry knowledge.
October 08, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Curaleaf is expanding its international presence, with Germany and Poland showing potential for growth similar to California's medical market. The UK is more pharmaceutical-focused, and Turkey's hemp industry offers opportunities.
Curaleaf's focus on international markets like Germany, Poland, and Turkey indicates potential revenue growth. The comparison to California's market suggests significant opportunities, while the pharmaceutical approach in the UK aligns with Curaleaf's medical cannabis focus.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
The international expansion of Curaleaf, a major player in the cannabis industry, could positively impact the AdvisorShares Pure US Cannabis ETF (MSOS) by increasing its exposure to growing markets.
As Curaleaf expands internationally, its growth could positively influence the MSOS ETF, which includes Curaleaf as a significant holding. The expansion into markets like Germany and Turkey could enhance the ETF's performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70